Li Yang-Qiu
Jinan University Medical College, Guangzhou 510632, Guangdong Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):851-6.
A20 was originally identified as a TNFα-induced protein 3 (TNFAIP3), a key regulator of inflammation signalling pathways, as well as a NF-κB inhibitor. It plays a critical role in regulation of innate and adoptive immunity. Recently, A20 has also been proposed to function as a tumor suppressor. Lacking A20 gene is involved in inflammation-mediated autoimmune disease and tumorigenesis in several human B-cell lymphomas. Current advance concerning the feature of A20 expression in immune cells, the biological function, the immune regulated function in native immunity, humoral and cellular immunity, the inactivation of A20 in lymphocytic malignancies and the polymorphism and abnormal expression of A20 in autoimmune disease indicate that the clinical significance of A20 should be worthy to recognize and to be further employed in induction of immune tolerance, antitumor immuno-regulated therapy and antiviral immunotherapy and so on.
A20最初被鉴定为肿瘤坏死因子α诱导蛋白3（TNFAIP3），是炎症信号通路的关键调节因子，也是一种核因子κB抑制剂。它在先天性和适应性免疫调节中起关键作用。最近，A20也被认为具有肿瘤抑制功能。A20基因缺失与炎症介导的自身免疫性疾病以及几种人类B细胞淋巴瘤的肿瘤发生有关。目前关于A20在免疫细胞中的表达特征、生物学功能、天然免疫、体液免疫和细胞免疫中的免疫调节功能、淋巴细胞恶性肿瘤中A20的失活以及自身免疫性疾病中A20的多态性和异常表达的研究进展表明，A20的临床意义值得认识，并应进一步应用于诱导免疫耐受、抗肿瘤免疫调节治疗和抗病毒免疫治疗等。
